<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510560</url>
  </required_header>
  <id_info>
    <org_study_id>FIT-04</org_study_id>
    <nct_id>NCT02510560</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutrinia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutrinia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of NTRA-2112 on intestinal malabsorption in preterm
      infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the efficacy and safety of NTRA-2112 on intestinal malabsorption in
      preterm infants as compared to placebo
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of days to achieve complete enteral feeding</measure>
    <time_frame>28 days or discharge from hosital</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days to achieve discharge from hospital or readiness to discharge</measure>
    <time_frame>28 days or discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth velocity (g/kg/day)</measure>
    <time_frame>28 days or discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Premature Birth of Newborn</condition>
  <condition>Intestinal Malabsorption</condition>
  <arm_group>
    <arm_group_label>NTRA-2112 A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTRA-2112 B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTRA-2112</intervention_name>
    <arm_group_label>NTRA-2112 A</arm_group_label>
    <arm_group_label>NTRA-2112 B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age
             matching (±2 weeks) between maternal dates and/or early antenatal ultrasound

          2. Birth weight ≥ 500g

          3. Singleton or twin birth

        Exclusion Criteria

        1. Complete enteral feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Anne Cox</last_name>
    <role>Study Director</role>
    <affiliation>Nutrinia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>FIT Clinical Manager</last_name>
    <phone>+972 3 7262262</phone>
    <email>info@nutrinia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AMC - Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Shamir R, Kolacek S, Koletzko S, Tavori I, Bader D, Litmanovitz I, Flidel-Rimon O, Marks KA, Sukhotnik I, Shehadeh N. Oral insulin supplementation in paediatric short bowel disease: a pilot observational study. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):108-11. doi: 10.1097/MPG.0b013e31819344db.</citation>
    <PMID>19503001</PMID>
  </reference>
  <reference>
    <citation>Shulman RJ. Effect of enteral administration of insulin on intestinal development and feeding tolerance in preterm infants: a pilot study. Arch Dis Child Fetal Neonatal Ed. 2002 Mar;86(2):F131-3.</citation>
    <PMID>11882558</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 22, 2016</lastchanged_date>
  <firstreceived_date>July 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
